The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.

First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

FDA 批准胰岛素门冬胰岛素（Merilog）作为胰岛素门冬胰岛素（Novolog）的生物类似药，用于改善成人和儿童糖尿病患者的血糖控制。该药是 FDA 批准使用的首个速效胰岛素生物类似药，标志着糖尿病治疗领域的一个重要里程碑。这是 FDA 批准的第三个胰岛素生物类似药。

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

(HealthDay News) — The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...

Merilog 100units/mL is supplied as both a 10mL multi-dose vial as well as a 3mL single-patient-use prefilled pen. The Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj ...

Mariposa California's original daily updated online newspaper is the premier site for news and information on Yosemite, ...